Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 3Withdrawn 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 3Thoracic 2Tumor-Agnostic 1Plasma cell 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 4Ovarian Neoplasms 2Breast Neoplasms 2Stomach Neoplasms 1Solid Tumor 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Lung Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Choriocarcinoma 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Bone Neoplasms 1Bone Diseases 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × saracatinib × Clear all
NCT00610714 2012-12-18

OVERT-1

AstraZeneca

Phase 2 Completed
211 enrolled 12 charts
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT00496028 2010-09-22

Phase I Study in Patients With Solid Tumours

AstraZeneca

Phase 1 Completed
148 enrolled
Tumor-Agnostic

Neoplasms

NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

NCT01000896 2010-02-04

Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

AstraZeneca

Phase 1 Withdrawn
27 enrolled
GynecologicThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡